# EDGAR Filing Document

**Accession Number:** 0001728328
**File Stem:** 0001213900-23-019851
**Filing Date:** 2023-3
**Character Count:** 12661
**Document Hash:** fc8d59d50f942f42dff887f6ce1eccea
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-23-019851.hdr.sgml**: 20230314

**ACCESSION NUMBER**: 0001213900-23-019851

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20230313

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230314

**DATE AS OF CHANGE**: 20230314

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** InMed Pharmaceuticals Inc.
- **CENTRAL INDEX KEY:** 0001728328
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39685
- **FILM NUMBER:** 23729981

**BUSINESS ADDRESS:**
- **STREET 1:** SUITE 310, 815 W. HASTINGS STREET
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V6C 1B4
- **BUSINESS PHONE:** (604) 669-7207

**MAIL ADDRESS:**
- **STREET 1:** SUITE 310, 815 W. HASTINGS STREET
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V6C 1B4

?xml version="1.0" encoding="utf-8"?

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**WASHINGTON, D.C. 20549** 

**FORM 8-K**

**CURRENT REPORT** 

**Pursuant to Section 13 or 15(d)** 

**of the Securities Exchange Act of 1934** 

**Date of Report (Date of earliest event reported): March 13, 2023**

**INMED PHARMACEUTICALS INC.** 

**(Exact Name of Company as Specified in Charter)** 

---

| | | |
|:---|:---|:---|
| **British Columbia** | **001-39685** | **98-1428279** |
| **(State or Other Jurisdiction<br> of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br> Identification No.)** |

---

---

| | |
|:---|:---|
| **InMed Pharmaceuticals Inc.** <br> **Suite 310 - 815 W. Hastings Street,** <br> **Vancouver, B.C.** <br> **Canada** | **V6C 1B4** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

**Company's telephone number, including area code: (604) 669-7207**

**Not applicable** 

**(Former Name or Former Address, if Changed Since Last Report)** 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange<br> on which registered** |
| **Common Shares, no par value** | **INM** | **The Nasdaq Stock Market LLC** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 7.01 Regulation FD Disclosure.**

On March 13, 2023, the Company announced that a peer-reviewed scientific study entitled "Rare phytocannabinoids exert anti-inflammatory effects on human keratinocytes via the endocannabinoid system and MAPK signalling pathway" has been published in the International Journal of Molecular Sciences.

The information set forth in this Item 7.01, including Exhibits 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits:

The following exhibits shall be deemed to be furnished, and not filed:

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1<br>| [News release, dated March 13, 2023](ea175184ex99-1_inmedpharma.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101) |

---

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | INMED PHARMACEUTICALS INC. | INMED PHARMACEUTICALS INC. |
| Date: March 14, 2023 | By: | /s/ Eric A Adams |
|  |  | Eric A Adams <br> President & CEO |

---

## Exhibit 99.1

**Exhibit 99.1**

---

| | |
|:---|:---|
| ![](ex99-1_001.jpg)<br>| **NASDAQ: INM**<br>Suite 310-815 W. Hastings St.<br> Vancouver, BC, Canada V6C 1B4<br> Tel: +1.604.669.7207<br> Email: info@inmedpharma.com<br> www.inmedpharma.com |

---

**InMed Announces Publication of Peer-Reviewed Study Showing the Anti-Inflammatory Potential of Rare Cannabinoids in Skin Conditions**

&nbsp;&nbsp;&nbsp;&nbsp;· Supports
the therapeutic potential of rare cannabinoids in inflammatory skin conditions such as atopic dermatitis,
psoriasis, pruritus, and acne

&nbsp;&nbsp;&nbsp;&nbsp;· Further
demonstrates the anti-inflammatory effects of CBC, THCV, CBG and CBGA

&nbsp;&nbsp;&nbsp;&nbsp;· Details
possible mechanisms of action on how rare cannabinoids can interact with specific skin-related endocannabinoid receptors

Vancouver, BC – March 13, 2023 – InMed Pharmaceuticals Inc. ("**InMed**" or the "**Company**") (**Nasdaq: INM**), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announced that a peer-reviewed scientific study entitled *"Rare phytocannabinoids exert anti-inflammatory effects on human keratinocytes via the endocannabinoid system and MAPK signalling pathway"* has been published in the International Journal of Molecular Sciences. This is the second such Company-sponsored study to demonstrate the anti-inflammatory effects of rare cannabinoids and their potential application for the treatment of skin conditions such as atopic dermatitis, psoriasis, pruritus, and acne.

The study, conducted in collaboration with Dr. Mauro Maccarrone at the Università degli Studi dell'Aquila, investigates the anti-inflammatory effects of the rare cannabinoids, cannabichromene (CBC), Δ9-tetrahydrocannabivarin (THCV), cannabigerol (CBG) and cannabigerolic acid (CBGA) on inflamed human keratinocytes (HaCaT cells) and elucidates the potential mechanism of action associated with these compounds in the skin.

Results demonstrate these rare cannabinoids significantly blocked inflammation by reducing the release of tested pro-inflammatory interleukins, including IL-1β, IL-8, IL-12, IL-31, IL-10 and tumor necrosis factor (TNF-β). Results showed that THCV and CBGA act synergistically with the endocannabinoid system elements to activate anti-inflammatory effects. This demonstration of the mechanism of action opens new perspectives for possible treatments of inflammation-related skin conditions.

"This study provides further evidence of the ability of rare cannabinoids to exert anti-inflammatory effects in human keratinocytes through modifications of the endocannabinoid system and MAPK signalling," said InMed's scientific advisor, Dr. Mauro Maccarrone, Professor and Chair of Biochemistry at the Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Italy. "Results from this study demonstrate important mechanisms of biological effects of rare cannabinoids and support the therapeutic potential of THCV and CBGA on inflammation-related skin conditions."

"Research into the biological activity of the rare cannabinoids has been limited to date and InMed continues to support this foundational research to further understand the pharmacological properties of these rare cannabinoids," said Dr. Eric Hsu, Senior VP, Preclinical Research and Development. "As we continue to build our pipeline of rare cannabinoid and cannabinoid analog therapeutics, evidence demonstrating the specific biological activity will be key in the selection and advancement of our programs."

The peer-reviewed publication can be found here: https://www.mdpi.com/1422-0067/24/3/2721

This study is a follow-on to a previously announced peer-reviewed publication in June 2022 analyzing the effects of various rare cannabinoids on the major endocannabinoid system elements in skin cells.

InMed is developing a pipeline of rare cannabinoids and cannabinoid analogs across a spectrum of therapeutic applications with large unmet medical needs. Our pharmaceutical programs include a Phase 2 clinical trial studying the safety and efficacy of cannabinol (CBN) cream for epidermolysis bullosa and preclinical programs in glaucoma and neurodegenerative disease.

**About InMed**

InMed Pharmaceuticals is a global leader in the research, development and manufacturing of rare cannabinoids, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs. We also have significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors. For more information, visit www.inmedpharma.com.

**Investor Contact:** 

Colin Clancy

Vice President, Investor Relations

and Corporate Communications

T: +1.604.416.0999

E: cclancy@inmedpharma.com

**Cautionary Note Regarding Forward-Looking Information:** 

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: showing the anti-inflammatory potential of rare cannabinoids in skin conditions; supporting the therapeutic potential of rare cannabinoids in inflammatory skin conditions such as atopic dermatitis, psoriasis, pruritus, and acne; possible mechanisms of action on how rare cannabinoids can interact with specific skin-related endocannabinoid receptors; blocking inflammation by reducing the release of tested pro-inflammatory interleukins, including IL-1β, IL-8, IL-12, IL-31, IL-10 and tumor necrosis factor; showing that THCV and CBGA act synergistically with the endocannabinoid system elements to activate anti-inflammatory effects; demonstrating the mechanism of action opens new perspectives for possible treatments of inflammation-related skin conditions; continuing to build our pipeline of rare cannabinoid and cannabinoid analog therapeutics; developing a pipeline of rare cannabinoids and cannabinoid analogs across a spectrum of therapeutic applications with large unmet medical needs; having significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors.

Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed's stand-alone business is disclosed in InMed's Annual Report on Form 10-K and other filings with the Securities and Exchange Commission on www.sec.gov.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.